NEW YORK, March 12, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Atreca, Inc. (“Atreca” or the “Company”) (NASDAQ: BCEL).   Such investors are.

We can judge whether Atreca, Inc. (NASDAQ:BCEL) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]

REDWOOD CITY, Calif., Nov. 14, 2019 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of.

Atreca has a highly differentiated approach to antibody drug discovery that moves completely away from the biologically or genetically derived hypotheses that are traditionally used to inform target selection, Willey said in a Monday initiation note.

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique.

Atreca, Inc. (Atreca) (BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it has entered into a strategic research collaboration with Merck (known as MSD outside the United States and Canada), to identify the antigenic targets of select antibodies discovered by Atreca with potential utility in oncology. “We are excited to collaborate with Merck, a global leader in oncology, to identify novel antibody targets that may hold the potential to transform the future treatment of cancer,” said John Orwin, Chief Executive Officer.

REDWOOD CITY, Calif., Nov. 05, 2019 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of.

Atreca, Inc. (Atreca) (BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the first patient has been dosed in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers. ATRC-101, a monoclonal antibody derived from a human antibody identified in a cancer patient via Atreca’s drug discovery platform, targets a ribonucleoprotein (RNP) complex and is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, to the company’s Board of Directors. In addition, Lawrence Steinman, M.D., Stanford University Professor and co-founder of Atreca, has resigned from the Board, effective as of August 22, 2019, but will continue to serve as a technical advisor to the company. “As we prepare to submit an Investigational New Drug (IND) application for ATRC-101 later this year and enter the clinic in early 2020, Lindsey’s deep oncology expertise and her experience in the development of oncology therapeutics will be critical as the company continues to evolve,” said John Orwin, Chief Executive Officer.

SOUTH SAN FRANCISCO, Calif., May 13, 2020 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated.

SOUTH SAN FRANCISCO, Calif., April 06, 2020 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique.

SOUTH SAN FRANCISCO, Calif., March 11, 2020 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application. Atreca expects to initiate a first-in-human Phase 1b clinical trial of ATRC-101 in patients with solid tumors in early 2020.

Every investor in Atreca, Inc. (NASDAQ:BCEL) should be aware of the most powerful shareholder groups. Institutions...

REDWOOD CITY, Calif., Aug. 13, 2019 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of.

One third of this year's Bay Area companies that went public in the past 12 months entered trading on the day after Christmas below their original offering prices.

REDWOOD CITY, Calif., Nov. 12, 2019 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of.

SOUTH SAN FRANCISCO, Calif., May 12, 2020 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique.

Ms. Ball brings more than 25 years of life sciences industry experience focused primarily on finance, corporate development and strategic planning. “We are pleased to announce the appointment of Kristine to our board of directors,” said John A. Orwin, Chief Executive Officer of Atreca.

SOUTH SAN FRANCISCO, Calif., May 14, 2020 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated.